15 Jun 2026

Novo Nordisk Partner Platform Expands Asset Library for eHealth Weight Management

A growing portfolio of digital and connected-device solutions is helping eHealth partners strengthen patient experiences across the weight-management journey

As more weight-management care includes online touchpoints, eHealth companies need practical ways to support education, measurement, nutrition, health indicators and follow-up within their own patient journeys. The Novo Nordisk Partner Platform is expanding its asset library to help address that need, with connected at-home measurement from Withings Health Solutions joining a curated portfolio that already spans digital body insight, nutrition intelligence and facial-scan health insights. The platform is designed to make high-quality digital capabilities easier for partners to discover, assess and integrate.

Weight-management journeys can change over time as users move from initial interest to ongoing support. The Partner Platform brings together assets that can strengthen specific points in that journey. Its ambition is to broaden partner portfolios with proven, streamlined offerings that improve the patient experience. This matters for eHealth companies balancing user experience, operational feasibility and speed of implementation across markets and teams.

Practically, the platform gives eHealth partners a structured way to explore available assets, understand what each capability is designed to support and begin access discussions. This helps partners identify which solutions are most relevant to their immediate needs, while keeping their brand, journey and operating model at the centre. It also makes it easier to compare where each asset could address a specific gap before implementation begins.

The expanded asset library is organized around complementary capabilities across connected measurement, digital body insight, nutrition support and vital-sign engagement, with each solution addressing a different part of the weight-management experience. Solutions include Prism Labs, Passio.ai, Withings Health Solutions and ComeStai, each bringing a distinct role to the broader portfolio and giving eHealth partners flexibility to choose the capabilities that best fit their strategy, market and user experience.

Mobile-phone body-composition scans — Prism Labs: Prism Labs uses a smartphone camera to help users better understand their physical changes beyond weight alone. The scan can capture 40+ body measurements and ratios, including waist-to-height ratio, waist circumference, lean muscle mass and body fat %. The experience can be embedded into partner apps or web flows, creating a low-friction engagement opportunity without requiring additional hardware. Because the interaction starts with a familiar device, it can support patient awareness, check-ins and follow-up conversations around body change at scale.

Nutrition intelligence — Passio.ai: Provides the nutrition intelligence layer for digital health and weight-management platforms. Through AI-powered food recognition, meal analysis, voice logging, barcode scanning, and nutrition APIs, Passio transforms everyday eating behaviours into structured, actionable insights. Partners can use this intelligence to power coaching experiences, personalized recommendations, meal planning, food scoring, commerce integrations, and behaviour-change interventions,helping bridge the gap between nutrition awareness and meaningful action.

Connected at-home measurement — Withings Health Solutions: Novo Nordisk and Withings are exlporing to add connected at-home measurement from Withings adds a continuous layer of engagement to digital weight-management journeys. The ecosystem includes connected scales, body-composition measurement and remote-monitoring capabilities that can bring health insights into partner platforms and workflows. This helps eHealth partners make progress more visible beyond individual consultations or app sessions and support users over time. Novo Nordisk and Withings are also exploring future opportunities around the evolving patient journey and how connected health experiences may support more personalized approaches to weight management. 

Facial-scan health insights — ComeStai: Facial-scan health insights from ComeStai create a short check-in through a web module or app. Using a one-minute facial video and rPPG technology, the solution can generate vital-parameter insights for informational and wellness-oriented use cases, depending on implementation and local requirements. It gives partners a simple way to add health-indicator engagement in a digital setting.

Together, these assets give eHealth partners a focused set of options across measurement, body insight, nutrition and health engagement. The Partner Platform improves the usefulness of the journey for patients.

The expansion reflects the direction of Novo Nordisk Partner Platform: a balanced portfolio of digital and connected-device solutions that partners can use according to their needs. No single solution is positioned as the answer for every use case. Each asset has a defined role, and the value comes from giving eHealth partners more choice in how they build better weight-management experiences.

eHealth companies can explore the Novo Nordisk Partner Platform asset library and request access to relevant digital or connected-device offerings through the platform. 

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen, Novo-B. Its ADRs are listed on the New York Stock Exchange, NVO. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Disclosure: This article was developed in collaboration with Novo Nordisk